How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Fibromyalgia Treatment Market
- By Treatment Type: Pharmacological Treatments, Non-Pharmacological Therapies, Complementary and Alternative Medicine
- By Pharmacological Treatments: Analgesics, Antidepressants, Anticonvulsants, Muscle Relaxants
- By Non-Pharmacological Therapies: Physical Therapy, Cognitive Behavioral Therapy, Exercise Therapy, Occupational Therapy
- By End User: Hospitals, Specialty Clinics, Home Care Settings, Ambulatory Care Centers
- By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Treatments leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Fibromyalgia Treatment Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 3
Pharmacological Treatments 4
Non-Pharmacological Therapies 4
End User 4
Distribution Channel 3
Companies profiled
Pfizer Inc.
Eli Lilly and Company
AbbVie Inc.
Jazz Pharmaceuticals plc
Mylan N.V. (now part of Viatris)
Teva Pharmaceutical Industries Ltd.
H. Lundbeck A/S
AstraZeneca plc
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Mitsubishi Tanabe Pharma Corporation
Grünenthal GmbH
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Jazz Pharmaceuticals plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bausch Health Companies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Grünenthal GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →UCB S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bristol-Myers Squibb Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Novartis AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,491M by 2033 · 8.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Treatments62.8
- Non-Pharmacological Therapies13.9
- Complementary and Alternative Medicine23.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$258.6M → $453.3M · 7.3%
Europe$180.2M → $314.1M · 7.2%
Asia Pacific$164.5M → $284.0M · 7.1%
Latin America$101.9M → $200.0M · 8.8%
Middle East and Africa$78.4M → $154.8M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.322026
8.342027
8.342028
8.362029
8.372030
8.382031
8.402032
8.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.27.2
- Eli Lilly and Company14.4
- AbbVie Inc.8.6
- Jazz Pharmaceuticals plc5.4
- Mylan N.V. (now part of Viatris)9.5
- Teva Pharmaceutical Industries Ltd.7.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type21.1%
Pharmacological Treatments16.4%
Non-Pharmacological Therapies26.9%
End User20.9%
Distribution Channel14.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.2
- Europe22.3
- Asia Pacific20.2
- Latin America14.2
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 80 | 74 | 95 | 89 | 79 | 75 | 82 |
| Eli Lilly and Company | 84 | 82 | 74 | 68 | 85 | 77 | 78 |
| AbbVie Inc. | 79 | 77 | 72 | 87 | 74 | 68 | 76 |
| Jazz Pharmaceuticals plc | 60 | 64 | 58 | 73 | 70 | 62 | 65 |
| Mylan N.V. (now part of Viatris) | 52 | 69 | 62 | 56 | 72 | 70 | 64 |
| Teva Pharmaceutical Industries Ltd. | 46 | 66 | 56 | 51 | 71 | 65 | 59 |
| H. Lundbeck A/S | 51 | 44 | 61 | 65 | 58 | 51 | 55 |
| AstraZeneca plc | 38 | 55 | 51 | 41 | 39 | 56 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Eli Lilly and Company
- AbbVie Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Eli Lilly and Company | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| AbbVie Inc. | ✓ | ◐ | − | ✓ | ✓ | ◐ |
| Jazz Pharmaceuticals plc | ◐ | − | − | ✓ | ◐ | − |
| Mylan N.V. (now part of Viatris) | − | ◐ | ✓ | ◐ | − | ✓ |
| Teva Pharmaceutical Industries Ltd. | − | ◐ | ◐ | − | ◐ | ◐ |
| H. Lundbeck A/S | ◐ | − | ◐ | − | ◐ | ◐ |
| AstraZeneca plc | − | ◐ | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.82
2Eli Lilly and Company78
3AbbVie Inc.76
4Jazz Pharmaceuticals plc65
5Mylan N.V. (now part of Viatris)64
6Teva Pharmaceutical Industries Ltd.59
7H. Lundbeck A/S55
8AstraZeneca plc47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Eli Lilly and Company
Challenger1
Strong scale, closing on the leaders.
AbbVie Inc.
Contender3
Focused players with pockets of strength.
Jazz Pharmaceuticals plcMylan N.V. (now part of Viatris)Teva Pharmaceutical Industries Ltd.
Niche2
Specialists in a single segment or region.
H. Lundbeck A/SAstraZeneca plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Fibromyalgia Treatment Market — a $174M beachhead inside a $3.39B market.
Beachhead (SOM)$174Mobtainable near-term
Serviceable (SAM)$1.19Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Pharmacological Treatments
Best fit — highest urgency & budget in Treatment Type.
Economic buyer81 fit
Non-Pharmacological Therapies
Strong fit — clear ROI and a fast path to value.
End user64 fit
Complementary and Alternative Medicine
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pharmacological Treatments & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Non-Pharmacological Therapies
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Fibromyalgia Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation12%
Closed-won8%
$10.4KCAC
$59KLTV
5.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Fibromyalgia Treatment Market is a resilient opportunity — $5.54B by 2033, compounding at 4.5%.
TAM · 2025$3.90Btoday
TAM · 2033$5.54Bforecast
CAGR4.5%2027–2033
Cumulative$42.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.54BTotal addressable market
SAM$2.00BServiceable available market
SOM$404MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.54BLarge & growingTAM by 2033 at 4.5% CAGR
$2.00BServiceable nowreachable with today’s model
$404MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.32BBear2.9% CAGR
$5.54BBase4.5% CAGR
$7.09BBull5.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pharmacological Treatments optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Fibromyalgia Treatment Market — a $3.72B market by 2033. Plan: grow share from 9.3% to 15.8%.
Market size · 2033$3.72Btotal addressable
Market CAGR6.4%2027–2033
Target share15.8%from 9.3% today
Revenue ambition$588Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.3% | 15.8% | At risk |
| Revenue | $378M | $588M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 28.6% | 41.2% | At risk |
| Customer retention | 85.4% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Pharmacological Treatments capability
A defensible second engine — invest in Pharmacological Treatments to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pharmacological Treatments
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $73M capacity & capability investment
- Greenlight bolt-on M&A in Pharmacological Treatments
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Fibromyalgia Treatment Market conversation — a $2.66B market you can size, segment and defend in minutes.
Market size · 2033$2.66Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers1,712+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Pfizer Inc.Eli Lilly and CompanyAbbVie Inc.Jazz Pharmaceuticals plcMylan N.V. (now part of Viatris)Teva Pharmaceutical Industries Ltd.H. Lundbeck A/SAstraZeneca plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Fibromyalgia Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Fibromyalgia Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Fibrin Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportFibrin Glue Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportChinese Patent Medicine Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportMonoclonal Antibodies Sterile Injectable Drugs Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAllopurinol Intermediate Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAnthelmintic Drugs Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportAllopurinol API Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportFabrazyme (agalsidase beta) Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportAllograft with Viable Cells Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportAllograft Tissue Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportEye Health Supplements Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportAllograft Putty Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.